Page 60 - LDR CLO

researchers. Further, this status has a halo e ect that re ects from Karmanos to all of McLaren’s facilities.
There is another “halo e ect” that Karmanos research brings to the McLaren system — widespread “best practices” in treatment. “One great success is that all McLaren oncologists now have uniform care plans
for patients throughout the system,” notes Dr. Bepler. “Formularies, infusion treatments, order of drugs, safety protocols — all this has
been harmonized, and is now the same whether a patient is treated in Petoskey or in Flint.”
Karmanos is not the only tool used for upgrading research and trials capabilities within McLaren Health Care. Our new McLaren Center for
70% of U.S. MEDIcAL RESEARch AND TRIALS fUNDINg GoeS to CoMMunItY hoSpItalS
Research and Innovation has been crucial to gathering all of our system’s research talents under a single administrative roof. The Center is building the infrastructure needed to establish a standardized, centralized hub for physicians and professionals to conduct clinical trials and research.
Among the landmarks of 2015 was full development of the Center’s Research Advisory Board. Launched at the end of last year, the RAB is the keystone of the Center’s oversight and accountability framework. Chaired by Dr. Hesham Gayar of McLaren Flint, its panel of skilled physicians, researchers, administrators and community leaders will o er strategic guidance for McLaren’s research programs. Other achievements of
the Center’s rst full year of operation include researching physician compensation and investigator agreements, and forming both a Cardiology Research Council and Protocol Review Committee. The result is a McLaren research entity that is an attractive model for industry researchers.
McLaren HeaLtH Care
15